Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 70

Results For "phase-3"

732 News Found

Novavax and Serum Institute receive EUA for Covid-19 vaccine in Indonesia
Biotech | November 02, 2021

Novavax and Serum Institute receive EUA for Covid-19 vaccine in Indonesia

The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice


Sun Pharma introduces treatment for plaque psoriasis in Canada
Drug Approval | October 28, 2021

Sun Pharma introduces treatment for plaque psoriasis in Canada

Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return


Novavax files for approval of its Covid-19 vaccine in the UK
Biotech | October 27, 2021

Novavax files for approval of its Covid-19 vaccine in the UK

Filing marks first protein-based vaccine submitted to MHRA for authorization


U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years
Drug Approval | October 22, 2021

U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option


Rakuten Medical partners with Karkinos Healthcare to expand novel cancer care in India
Biotech | October 22, 2021

Rakuten Medical partners with Karkinos Healthcare to expand novel cancer care in India

This strategic collaboration will enable continued innovation in cancer care


AstraZeneca India opens clinical data and insights division
News | October 20, 2021

AstraZeneca India opens clinical data and insights division

The division is expected to grow to over a 100-member strong team by 2022


Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
Biotech | October 18, 2021

Imfinzi plus tremelimumab significantly improved overall survival in liver cancer

The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
News | October 11, 2021

Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir

If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19


Takeda to collaborate with JCR Pharma to commercialise next-gen Hunter Syndrome therapy
Biotech | October 01, 2021

Takeda to collaborate with JCR Pharma to commercialise next-gen Hunter Syndrome therapy

Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval